DOI: 10.1097/qco.0000000000001075 ISSN: 0951-7375

Progress towards effective vaccines for Chlamydia trachomatis

Amanda L. Collar, Kathryn M. Frietze
Show PDF Cite

Purpose of review

Effective vaccines to prevent sexually transmitted Chlamydia trachomatis (Ct) infection have eluded researchers for decades. However, recent studies of a promising vaccine in human trials, and emerging understanding of the complexity of the natural immune response to infection have provided hope for the eventual approval of a vaccine. This review highlights recent progress toward developing effective vaccines for Ct.

Recent findings

In 2019, the first-in-human Ct vaccine, CTH522, Phase I/IIB trial was reported. Recent studies of this vaccine and its derivatives have further established CTH522 as the lead vaccine against sexually transmitted Ct. A variety of vaccines have entered the preclinical development pipeline, with researchers reporting efforts to target non-MOMP antigens, include novel adjuvants in vaccine formulations, and use alternative routes of administration to increase efficacy.

Summary

While the approval of a vaccine for Ct is closer than ever, the need for careful consideration of future implementation is especially important for the successful clinical translation of Ct vaccines into humans.

More from our Archive